Zacks Investment Research Lowers Oxford Immunotec Global PLC (NASDAQ:OXFD) to Sell

Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) from a hold rating to a sell rating in a research report released on Saturday morning.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Several other equities analysts have also issued reports on OXFD. Cowen and Company reaffirmed a buy rating and issued a $22.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Piper Jaffray Companies reaffirmed a buy rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. ValuEngine raised Oxford Immunotec Global PLC from a sell rating to a hold rating in a report on Friday, June 2nd. Finally, BTIG Research reaffirmed a buy rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $21.00.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 18.02 on Friday. Oxford Immunotec Global PLC has a 52-week low of $8.88 and a 52-week high of $19.51. The firm’s market capitalization is $415.83 million. The stock has a 50 day moving average price of $16.18 and a 200-day moving average price of $14.93.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.32). The company had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. Oxford Immunotec Global PLC’s quarterly revenue was up 35.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.29) earnings per share. Equities analysts forecast that Oxford Immunotec Global PLC will post ($1.07) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Lowers Oxford Immunotec Global PLC (NASDAQ:OXFD) to Sell” was published by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/08/08/zacks-investment-research-lowers-oxford-immunotec-global-plc-nasdaqoxfd-to-sell.html.

In other Oxford Immunotec Global PLC news, COO Peter Edwardson sold 10,000 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $14.66, for a total transaction of $146,600.00. Following the sale, the chief operating officer now owns 125,015 shares in the company, valued at $1,832,719.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Peter Wrighton-Smith sold 30,000 shares of the stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $16.06, for a total value of $481,800.00. Following the sale, the chief executive officer now owns 491,668 shares in the company, valued at approximately $7,896,188.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,085 shares of company stock valued at $1,710,328. 7.58% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. Neuberger Berman Group LLC increased its stake in Oxford Immunotec Global PLC by 143.6% in the first quarter. Neuberger Berman Group LLC now owns 134,229 shares of the company’s stock valued at $2,079,000 after buying an additional 79,129 shares in the last quarter. American International Group Inc. increased its stake in Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after buying an additional 904 shares in the last quarter. TFS Capital LLC increased its stake in Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock valued at $219,000 after buying an additional 2,337 shares in the last quarter. Denver Investment Advisors LLC increased its stake in Oxford Immunotec Global PLC by 47.5% in the first quarter. Denver Investment Advisors LLC now owns 30,880 shares of the company’s stock valued at $478,000 after buying an additional 9,949 shares in the last quarter. Finally, Parkwood LLC bought a new stake in Oxford Immunotec Global PLC during the first quarter valued at about $176,000. Hedge funds and other institutional investors own 87.03% of the company’s stock.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply